TY - JOUR
T1 - Intracellular leptin signaling following effective weight loss
AU - Sahin-Efe, Ayse
AU - Polyzos, Stergios A.
AU - Dincer, Fadime
AU - Zaichenko, Lesya
AU - McGovern, Rosemary
AU - Schneider, Benjamin
AU - Mantzoros, Christos S.
N1 - Funding Information:
This study was supported by the Award 1I01CX000422-01A1 from the Clinical Science Research and Development Service of the VA Office of Research and Development .
Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2015
Y1 - 2015
N2 - Aim. To investigate the effect of ex-vivo leptin treatment before and after weight loss on key-molecules of intracellular leptin signaling in peripheral blood mononuclear cells (PBMCs) of obese women. Materials and methods. Five healthy obese women underwent a 12-week medical nutrition treatment aiming at inducing 10% weight loss. Isolated PBMCs at baseline, and at weeks 8 and 12 were treated with increasing leptin doses (0, 25 and 75 ng/ml) for 30 min. The phosphorylation of signal transducer and activator of transcription (STAT)3, extracellularsignal- regulated kinase (ERK), protein kinase B (Akt) and 5' adenosine monophosphateactivated protein kinase (AMPK) of PBMCs was analyzed usingWestern blotting. Results. Women lost 10 ± 1% and 13 ± 1% of weight at week 8 and 12, respectively. Circulating leptin and insulin significantly decreased from 39.5 ± 7.7 to 12.2 ± 2.4 ng/ml (p = 0.026) and from 13.0 ± 1.6 to 5.4 ± 0.9 μU/ml (p = 0.005) at week 12, respectively. In the ex vivo study, a significant decrease in STAT3 phosphorylation was observed in the control group after weight loss. Treatment of PBMCs with leptin 75 ng/ml increased significantly ERK, STAT3 and Akt phosphorylation, but no weight loss induced change was observed in response to leptin treatment ex vivo. Conclusions. A 10%-15% weight loss decreases baseline STAT3 phosphorylation ex vivo, but does not alter the effect of increasing doses of leptin on the incremental intracellular phosphorylation of STAT3, ERK, Akt and AMPK. Supraphysiologic leptin doses (75 ng/ml) result in higher protein phosphorylation compared to either physiologic doses or no treatment, before and after weight loss.
AB - Aim. To investigate the effect of ex-vivo leptin treatment before and after weight loss on key-molecules of intracellular leptin signaling in peripheral blood mononuclear cells (PBMCs) of obese women. Materials and methods. Five healthy obese women underwent a 12-week medical nutrition treatment aiming at inducing 10% weight loss. Isolated PBMCs at baseline, and at weeks 8 and 12 were treated with increasing leptin doses (0, 25 and 75 ng/ml) for 30 min. The phosphorylation of signal transducer and activator of transcription (STAT)3, extracellularsignal- regulated kinase (ERK), protein kinase B (Akt) and 5' adenosine monophosphateactivated protein kinase (AMPK) of PBMCs was analyzed usingWestern blotting. Results. Women lost 10 ± 1% and 13 ± 1% of weight at week 8 and 12, respectively. Circulating leptin and insulin significantly decreased from 39.5 ± 7.7 to 12.2 ± 2.4 ng/ml (p = 0.026) and from 13.0 ± 1.6 to 5.4 ± 0.9 μU/ml (p = 0.005) at week 12, respectively. In the ex vivo study, a significant decrease in STAT3 phosphorylation was observed in the control group after weight loss. Treatment of PBMCs with leptin 75 ng/ml increased significantly ERK, STAT3 and Akt phosphorylation, but no weight loss induced change was observed in response to leptin treatment ex vivo. Conclusions. A 10%-15% weight loss decreases baseline STAT3 phosphorylation ex vivo, but does not alter the effect of increasing doses of leptin on the incremental intracellular phosphorylation of STAT3, ERK, Akt and AMPK. Supraphysiologic leptin doses (75 ng/ml) result in higher protein phosphorylation compared to either physiologic doses or no treatment, before and after weight loss.
KW - Leptin
KW - Leptin signaling
KW - Obesity
KW - STAT3
KW - Weight loss
UR - http://www.scopus.com/inward/record.url?scp=84942917925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942917925&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2015.04.006
DO - 10.1016/j.metabol.2015.04.006
M3 - Article
C2 - 25998856
AN - SCOPUS:84942917925
SN - 0026-0495
VL - 64
SP - 888
EP - 895
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
IS - 8
ER -